SUMO2 and glioblastoma: In order to facilitate the drug screening research, we found that both freshly derived patient GBM cell lines from HGCC (GEO-GSE72217, https://www.hgcc.se/, available for research) and other sources [Stringer et al., SRA-PRJNA508446] [41] as well as classically used GBM tumour cell lines (https://portals.broadinstitute.org/ccle), consistently upregulated transcriptome of SUMO2 (Fig. 2F and Additional file 4: Table S28), hence can be alternately used for anti-SUMO2 drug discovery.